Table 3 DENV antivirals that are currently undergoing clinical trials
From: Dengue virus pathogenesis and host molecular machineries
Drug Name | Target | Clinical Data | References |
|---|---|---|---|
JNJ-1802 | NS4B inhibitor | Phase- 2 (NCT05201794) | [122] |
UV-4B | Inhibits endogenous alpha glucosidase | Phase 1a clinical trial (NCT02061358) | [144] |
AT-752 | Inhibits NS5 RdRp function | Phase 1 (NCT05366439) and phase 2(NCT05466240) clinical trials are in progress | [145] |
Zanamivir | Blocks desialylation on platelet membrane by acting as neuraminidase inhibitor | Early Phase 1 (NCT04597437) | [146] |
Ivermectin | Inhibits the host nuclear import proteins important for nuclear exchange of the dengue NS5 protein | Phase 2/ 3 (NCT02045069) | [140] |
Ketotifen | Prevent mast cell degranulation | Phase 4 (NCT02673840) | [147] |